Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE-Lung: Afatinib + Cetuximab in EGFR-mutated NSCLC
NCT02716311Phase 2Completed
- Sponsor
- IFCT
- Start
- May 2016
- Primary completion
- Feb 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by IFCT. Primary endpoint: Time to Treatment Failure at 9 months. Started May 2016; status: completed.
02
Drugs
cetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02716311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02716311.